• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Kerecis to Acquire Swiss Life-Science Company Phytoceuticals, Gains Approval of Kerecis Omega3 Wound for Reimbursement in Switzerland

Share:

February 11, 2019

Kerecis, the company pioneering the use of fish skin in tissue regeneration, today received a notice from Swiss healthcare authorities that the company’s lead product, Kerecis Omega3 Wound, will be reimbursed in Switzerland. The company will also acquire the Swiss life-science company Phytoceuticals. The aim of the acquisition is to establish sales in Switzerland and strengthen Kerecis’ position in Europe in the field of regenerative treatment of tissue and organ damage.

As of March 1, 2019, Swiss doctors will be able to use Kerecis Omega3 Wound for the treatment of hard-to-heal wounds showing no or very little healing progress under an adequate causal/local four-week therapy. The innovative fish-skin-based skin substitute has demonstrated clinical efficacy and cost-effectiveness when used on such wounds. This approach has now been confirmed by the decision of the Swiss healthcare authorities.

Regenerative Technologies Based on Fatty Acids
The products of both Kerecis and Phytoceuticals are rich in naturally occurring Omega fatty acids, which offer multiple health benefits and support the regeneration of damaged human tissue.
Kerecis Omega3 is intact fish skin that, when grafted onto damaged human tissue such as a diabetic or burn wound, recruits the body’s own cells and ultimately is converted into living tissue. The Kerecis products help the body regenerate damaged tissue because of the structure of the fish skin and the presence of Omega3 polyunsaturated fatty acids.

Phytoceuticals’ products, 1 PRIMARY WOUND DRESSING and WOUND, contain Omega fatty acids from natural oils. The products support the healing of post-surgical wounds and minor burns with little or no scarring. In some cases, using the Kerecis and Phytoceuticals products sequentially on the same wound leads to excellent results.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Switzerland is a single-payer healthcare system with 8.5 million people and the second-highest healthcare budget per capita after the United States. In the past 15 years, the number of people with diabetes in Switzerland has doubled,” said G. Fertram Sigurjonsson, CEO of Kerecis. “It is estimated that 50,000 people in Switzerland suffer from diabetic-related wounds resulting in approximately 7,500 amputations annually. Phytoceuticals has made good initial inroads in the Swiss market by treating diabetic patients with our combined technologies. We have had good results and believe the combination of our technologies and talents will make a stronger global company.”

“We are thrilled by the decision of the Swiss healthcare authorities to now reimburse Kerecis in Switzerland for outpatient care,” said Eduardo Theiler, CEO of Phytoceuticals. “When we introduced Kerecis Omega3 to Swiss doctors, it became clear to us that the product has great potential here in Switzerland and for all of Europe, where tissue damage, including diabetic wounds due to the diabetic epidemic, is on the rise.”

Eduardo Theiler, the CEO of Phytoceuticals, will be responsible for Kerecis’ operations in Europe in the integrated company. The acquisition is pending the approval of the shareholders of both companies and is expected to close in the first quarter 2019.

Date: February 11, 2019

Source: Kerecis

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Eisai buys out Purdue rights to end collaborationEisai buys out Purdue rights to end collaboration
  • GetWellNetwork, Cerner Deploy Free COVID-19 Solutions to all ClientsGetWellNetwork, Cerner Deploy Free COVID-19 Solutions to all Clients
  • Generational Equity Advises East Hills Family Pharmacy in Sale to Rite AidGenerational Equity Advises East Hills Family Pharmacy in Sale to Rite Aid
  • Digital IBS Therapy Startup MetaMe Partners to Bring PDT to MarketDigital IBS Therapy Startup MetaMe Partners to Bring PDT to Market
  • New York regulator has concerns on CVS dealNew York regulator has concerns on CVS deal
  • Tech consortium including Google, Microsoft and more sets benchmarks for AI performanceTech consortium including Google, Microsoft and more sets benchmarks for AI performance
  • RRD International Acquired By Uniphar, A Global Diversified Healthcare Services CompanyRRD International Acquired By Uniphar, A Global Diversified Healthcare Services Company
  • Elsevier Buys 3d Anatomy Technology Company 3d4medicalElsevier Buys 3d Anatomy Technology Company 3d4medical

Trending This Week

  • Pharmaceutical Lipids Market Revenue, Key Players, Dynamic, Demand and Drives, Forecast to 2031
  • Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market Report 2022: A $34+ Billion Market in 2026 – Long-Term Forecast to 2031
  • Drug Discovery Services Market to 2027 – Size, Share & Industry Trends Analysis Report | Emergen Research
  • Global Nanomedicine Market, By Nanomolecule Type, By Nanoparticle Type, By Application By Disease Indication, By Region and Competition Forecast & Opportunities, 2027
  • Pharmaceutical Waste Disposal Services Market Size 2022 Analysis By Business Share, Strategies, Investment Opportunities, Revenue Expectation, Future Trends, Prominent Players, Industry Impact and Global Forecast Till 2025
  • AstraZeneca Rumored to Have Set Sights on Mereo BioPharma Buyout

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications